



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Operations Office

Date: January 26, 2007

To: NCCTG Primary Clinical Research Associates

From: Laura Denton, Protocol Development Coordinator

Re: N04C2, An Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR[®] Depot) for Symptomatic Ascites in Cancer Patients

Cancer Control specific forms instructions have been created for this study and the VEGF Specimen Submission Form has been revised to indicate that this form is completed only if a paracentesis is done.

If you have any questions, please feel free to contact me at 507/538-1802.

Thank you.